Zydus Lifesciences has been granted a patent for a stable oral liquid pharmaceutical composition containing vigabatrin, preservatives, and various agents, maintaining low impurity levels over three months at room temperature. The composition’s pH ranges from 5 to 8, ensuring effective delivery of the active ingredient. GlobalData’s report on Zydus Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of July 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12016857B2 outlines a liquid pharmaceutical composition primarily containing vigabatrin, or its pharmaceutically acceptable salts, in concentrations ranging from 0.1 wt % to 20 wt %. The composition is designed to include various additional components such as preservatives, buffering agents, sweeteners, flavoring agents, and optional excipients like solubilizers, antioxidants, and coloring agents. Notably, the formulation is stable for up to three months at room temperature, maintaining total impurities below 0.06% during this period. The claims specify that the composition can be free of polyhydric alcohols with 2 to 6 carbon atoms, ensuring a tailored formulation for therapeutic efficacy.
Further claims detail specific ingredients and their concentrations, including a preferred vigabatrin range of 5 wt % to 15 wt %. Preservatives such as methyl and propyl 4-hydroxy benzoate, sweeteners like maltitol and sucralose, and a variety of flavoring agents derived from natural and synthetic sources are also specified. The flavoring agents encompass a wide range of options, including various fruit essences and citrus oils. The composition is characterized by a pH range of 5 to 8, enhancing its stability and usability. Overall, the patent presents a comprehensive formulation aimed at providing a stable and palatable liquid medication for patients requiring vigabatrin.
To know more about GlobalData’s detailed insights on Zydus Lifesciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
